Guggenheim started coverage on shares of Zoetis (NYSE:ZTS) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set a “buy” rating on the stock.
A number of other equities analysts have also commented on the company. UBS Group initiated coverage on Zoetis in a research note on Wednesday, January 23rd. They issued a “neutral” rating and a $86.00 price objective on the stock. Zacks Investment Research raised Zoetis from a “sell” rating to a “hold” rating in a research note on Saturday, January 26th. Credit Suisse Group boosted their price target on Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a research note on Tuesday, April 2nd. Stifel Nicolaus raised Zoetis from a “hold” rating to a “buy” rating and boosted their price target for the company from $97.00 to $110.00 in a research note on Monday, March 4th. Finally, SunTrust Banks started coverage on Zoetis in a research note on Tuesday, March 19th. They issued a “hold” rating and a $100.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and an average target price of $103.15.
Shares of ZTS stock opened at $102.94 on Thursday. Zoetis has a 12 month low of $78.90 and a 12 month high of $103.97. The stock has a market cap of $49.00 billion, a PE ratio of 32.89, a PEG ratio of 2.56 and a beta of 0.91. The company has a current ratio of 4.05, a quick ratio of 2.79 and a debt-to-equity ratio of 2.84.
In other news, CEO Juan Ramon Alaix sold 312,109 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $94.06, for a total transaction of $29,356,972.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Roman Trawicki sold 17,873 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $95.10, for a total value of $1,699,722.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 447,975 shares of company stock valued at $42,728,902. Corporate insiders own 0.29% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Oregon Public Employees Retirement Fund increased its holdings in shares of Zoetis by 9,042.7% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 14,335,563 shares of the company’s stock valued at $168,000 after acquiring an additional 14,178,765 shares in the last quarter. FMR LLC grew its holdings in Zoetis by 209.7% during the fourth quarter. FMR LLC now owns 7,245,748 shares of the company’s stock worth $619,801,000 after buying an additional 4,905,887 shares in the last quarter. Norges Bank bought a new stake in Zoetis during the fourth quarter worth $404,080,000. Two Sigma Advisers LP grew its holdings in Zoetis by 947.4% during the fourth quarter. Two Sigma Advisers LP now owns 1,149,111 shares of the company’s stock worth $98,295,000 after buying an additional 1,039,400 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in Zoetis by 167.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,607,247 shares of the company’s stock worth $137,484,000 after buying an additional 1,005,212 shares in the last quarter. Hedge funds and other institutional investors own 90.95% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What is a Fiduciary?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.